{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T11:51:00Z","timestamp":1788177060003,"version":"build-2803163510"},"reference-count":111,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2014,3,12]],"date-time":"2014-03-12T00:00:00Z","timestamp":1394582400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2014,7]]},"DOI":"10.1007\/s10072-014-1701-0","type":"journal-article","created":{"date-parts":[[2014,3,11]],"date-time":"2014-03-11T17:53:42Z","timestamp":1394560422000},"page":"983-993","source":"Crossref","is-referenced-by-count":81,"title":["Anticonvulsant drugs and hematological disease"],"prefix":"10.1007","volume":"35","author":[{"given":"A.","family":"Verrotti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Scaparrotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Grosso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Chiarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Coppola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,3,12]]},"reference":[{"key":"1701_CR1","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1093\/oso\/9780195368215.003.0018","volume-title":"Antiepileptic drugs: a clinician\u2019s manual","author":"AA Asadi-Pooya","year":"2009","unstructured":"Asadi-Pooya AA, Sperling MR (2009) Antiepileptic drugs and hematological disorders. Antiepileptic drugs: a clinician\u2019s manual. Oxford University Press, New York, pp 165\u2013170"},{"key":"1701_CR2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clineuro.2009.10.011","volume":"112","author":"A Verrotti","year":"2010","unstructured":"Verrotti A, Coppola G, Parisi P et al (2010) Bone and calcium metabolism and antiepileptic drugs. Clin Neurol Neurosurg 112:1\u201310","journal-title":"Clin Neurol Neurosurg"},{"key":"1701_CR3","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1093\/oso\/9780195368215.003.0003","volume-title":"Antiepileptic drugs: a clinician\u2019s manual","author":"AA Asadi-Pooya","year":"2009","unstructured":"Asadi-Pooya AA, Sperling MR (2009) Mechanisms of actions and pharmacokinetic properties of antiepileptic drugs. Antiepileptic drugs: a clinician\u2019s manual. Oxford University Press, New York, pp 69\u2013148"},{"key":"1701_CR4","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1159\/000206797","volume":"70","author":"L Conti","year":"1983","unstructured":"Conti L, Gandolfo GM (1983) Benzodiazepine-induced thrombocytopenia. Demonstration of drug-dependent platelet antibodies in two cases. Acta Haematol 70:386\u2013388","journal-title":"Acta Haematol"},{"key":"1701_CR5","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1136\/bmj.296.6632.1332-b","volume":"296","author":"S El-Sayed","year":"1988","unstructured":"El-Sayed S, Symonds RP (1988) Lorazepam induced pancytopenia. Brit Med J 296:1332","journal-title":"Brit Med J"},{"key":"1701_CR6","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/1756-8722-3-24","volume":"3","author":"MA Bautista-Quach","year":"2010","unstructured":"Bautista-Quach MA, Liao YM, Hsueh CT (2010) Pancytopenia associated with clonazepam. J Hematol Oncol 3:24","journal-title":"J Hematol Oncol"},{"key":"1701_CR7","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1136\/bmj.4.5994.462","volume":"4","author":"RM Veall","year":"1975","unstructured":"Veall RM, Hogarth HC (1975) Thrombocytopenia during treatment with clonazepam. Br Med J 4:462","journal-title":"Br Med J"},{"key":"1701_CR8","first-page":"1236","volume":"3","author":"R Bussien","year":"1974","unstructured":"Bussien R (1974) Acute granulocytopenia after simultaneous administration of gentamicin and diazepam. Nouv Presse Med 3:1236","journal-title":"Nouv Presse Med"},{"key":"1701_CR9","first-page":"321","volume":"546","author":"RM Baumes","year":"1971","unstructured":"Baumes RM (1971) Drug induced cytopenia: acute thrombopenic purpura and active antiplatelet antibodies in the presence of valium. Maroc Med 546:321\u2013324","journal-title":"Maroc Med"},{"key":"1701_CR10","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1002\/(SICI)1096-8652(199909)62:1<52::AID-AJH9>3.0.CO;2-E","volume":"62","author":"T Ishikita","year":"1999","unstructured":"Ishikita T, Ishiguro A, Fujisawa K et al (1999) Carbamazepine-induced thrombocytopenia defined by a challenge test. Am J Hematol 62:52\u201355","journal-title":"Am J Hematol"},{"key":"1701_CR11","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1111\/j.1528-1167.2006.00596.x","volume":"47","author":"KB Handoko","year":"2006","unstructured":"Handoko KB, Souverein PC, van Staa TP et al (2006) Risk of aplastic anemia in patients using antiepileptic drugs. Epilepsia 47:1232\u20131236","journal-title":"Epilepsia"},{"key":"1701_CR12","volume-title":"The drug etiology of agranulocytosis and aplastic anemia","author":"DWKJ Kaufman","year":"1991","unstructured":"Kaufman DWKJ, Levy M, Shapiro S (1991) The drug etiology of agranulocytosis and aplastic anemia. Oxford University Press, New York"},{"key":"1701_CR13","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1002\/j.1875-9114.1998.tb03148.x","volume":"18","author":"SC Blackburn","year":"1998","unstructured":"Blackburn SC, Oliart AD, Garcia Rodriguez LA et al (1998) Antiepileptics and blood dyscrasias: a cohort study. Pharmacotherapy 18:1277\u20131283","journal-title":"Pharmacotherapy"},{"key":"1701_CR14","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1532\/IJH97.07027","volume":"86","author":"M Yamamoto","year":"2007","unstructured":"Yamamoto M, Suzuki N, Hatakeyama N et al (2007) Carbamazepine-induced hemolytic and aplastic crises associated with reduced glutathione peroxidase activity of erythrocytes. Int J Hematol 86:325\u2013328","journal-title":"Int J Hematol"},{"key":"1701_CR15","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/S0387-7604(97)00580-9","volume":"19","author":"T Tagawa","year":"1997","unstructured":"Tagawa T, Sumi K, Uno R et al (1997) Pure red cell aplasia during carbamazepine monotherapy. Brain Dev 19:300\u2013302","journal-title":"Brain Dev"},{"key":"1701_CR16","first-page":"655","volume":"46","author":"C Chandra Sekhar","year":"1998","unstructured":"Chandra Sekhar C, Ramana Reddi V, Srinivas B, Naik KR (1998) Pure red cell aplasia associated with carbamazepine. J Assoc Physicians India 46:655\u2013656","journal-title":"J Assoc Physicians India"},{"key":"1701_CR17","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1157\/13128685","volume":"208","author":"G Fraile","year":"2008","unstructured":"Fraile G, S\u00e1nchez D, Achecar L, Ferrere F (2008) Pure red cell aplasia secondary to carbamazepine. Rev Clin Esp 208:533\u2013534","journal-title":"Rev Clin Esp"},{"key":"1701_CR18","first-page":"496","volume":"52","author":"M Tohen","year":"1991","unstructured":"Tohen M, Castillo J, Cole JO et al (1991) Thrombocytopenia associated with carbamazepine: a case series. J Clin Psychiatry 52:496\u2013498","journal-title":"J Clin Psychiatry"},{"key":"1701_CR19","first-page":"378","volume":"53","author":"MA Gordon","year":"1992","unstructured":"Gordon MA (1992) Carbamazepine-associated thrombocytopenia. J Clin Psychiatry 53:378\u2013379","journal-title":"J Clin Psychiatry"},{"key":"1701_CR20","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1176\/ajp.150.5.844-a","volume":"150","author":"T Terao","year":"1993","unstructured":"Terao T (1993) Transient thrombocytopenia while continuing carbamazepine. Am J Psychiatry 150:1750\u20131751","journal-title":"Am J Psychiatry"},{"key":"1701_CR21","first-page":"1034","volume":"145","author":"I Drury","year":"1988","unstructured":"Drury I, Vanderzant CW (1988) Carbamazepine-induced isolated thrombocytopenia. Am J Psychiatry 145:1034","journal-title":"Am J Psychiatry"},{"key":"1701_CR22","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1007\/BF01953999","volume":"152","author":"K Kaneko","year":"1993","unstructured":"Kaneko K, Igarashi J, Suzuki Y et al (1993) Carbamazepine-induced thrombocytopenia and leucopenia complicated by Henoch\u2013Schonlein purpura symptoms. Eur J Pediatr 152:769\u2013770","journal-title":"Eur J Pediatr"},{"key":"1701_CR23","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/BF01954091","volume":"152","author":"T Konishi","year":"1993","unstructured":"Konishi T, Naganuma Y, Hongo K et al (1993) Carbamazepine-induced skin rash in children with epilepsy. Eur J Pediatr 152:605\u2013608","journal-title":"Eur J Pediatr"},{"key":"1701_CR24","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1056\/NEJMra066469","volume":"357","author":"RH Aster","year":"2007","unstructured":"Aster RH, Bougie DW (2007) Drug-induced immune thrombocytopenia. N Engl J Med 357:580\u2013587","journal-title":"N Engl J Med"},{"key":"1701_CR25","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.bcmd.2012.01.003","volume":"48","author":"AT Taher","year":"2012","unstructured":"Taher AT, Arabi M, Sibai H et al (2012) Carbamazepine-induced thrombocytopenia. Blood Cells Mol Dis 48:197\u2013198","journal-title":"Blood Cells Mol Dis"},{"key":"1701_CR26","doi-asserted-by":"crossref","first-page":"886","DOI":"10.7326\/0003-4819-129-11_Part_1-199812010-00009","volume":"129","author":"JN George","year":"1998","unstructured":"George JN, Raskob GE, Shah SR et al (1998) Drug-induced thrombocytopenia: a systematic review of published case reports. Ann Intern Med 129:886\u2013890","journal-title":"Ann Intern Med"},{"key":"1701_CR27","unstructured":"Royer D, George JN, Terrel DR (2011) Drug-induced thrombocytopenia. http:\/\/www.ouhsc.edu\/platelets\/ditp.html"},{"key":"1701_CR28","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/j.1440-1819.1995.tb01860.x","volume":"49","author":"M Kimura","year":"1995","unstructured":"Kimura M, Yoshino K, Maeoka Y, Suzuki N (1995) Carbamazepine-induced thrombocytopenia and carbamazepine-10,11-epoxide: a case report. Psychiatry Clin Neurosci 49:69\u201370","journal-title":"Psychiatry Clin Neurosci"},{"key":"1701_CR29","first-page":"132","volume":"51","author":"JS Goraya","year":"2003","unstructured":"Goraya JS, Virdi VS (2003) Carbamazepine-induced immune thrombocytopenia. Neurol India 51:132\u2013133","journal-title":"Neurol India"},{"key":"1701_CR30","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1136\/pgmj.56.659.665","volume":"56","author":"CW Owens","year":"1980","unstructured":"Owens CW, Parker NE, Nunn PP, Davies J (1980) Agranulocytosis associated with carbamazepine, and a positive reaction with anti-lymphoid leukaemia antiserum during recovery. Postgrad Med J 56:665\u2013668","journal-title":"Postgrad Med J"},{"key":"1701_CR31","first-page":"510","volume":"89","author":"L Banfi","year":"1998","unstructured":"Banfi L, Ceppi M, Colzani M et al (1998) Carbamazepine-induced agranulocytosis. Apropos of 2 cases. Recenti Prog Med 89:510\u2013513","journal-title":"Recenti Prog Med"},{"key":"1701_CR32","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/S0750-7658(99)80129-4","volume":"18","author":"S Cambon","year":"1999","unstructured":"Cambon S, Rossi P, Miliani Y et al (1999) Severe agranulocytosis induced by carbamazepine (Tegretol). Ann Fr Anesth Reanim 18:542\u2013546","journal-title":"Ann Fr Anesth Reanim"},{"key":"1701_CR33","first-page":"73","volume":"37","author":"L Olcay","year":"1995","unstructured":"Olcay L, Pekcan S, Yalnizo\u011flu D et al (1995) Fatal agranulocytosis developed in the course of carbamazepine therapy. A case report and review of the literature. Turk J Pediatr 37:73\u201377","journal-title":"Turk J Pediatr"},{"key":"1701_CR34","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1176\/ajp.141.5.687","volume":"141","author":"DJ Luchins","year":"1984","unstructured":"Luchins DJ (1984) Fatal agranulocytosis in a chronic schizophrenic patient treated with carbamazepine. Am J Psychiatry 141:687\u2013688","journal-title":"Am J Psychiatry"},{"key":"1701_CR35","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1176\/ajp.152.2.287","volume":"152","author":"M Tohen","year":"1995","unstructured":"Tohen M, Castillo J, Baldessarini RJ et al (1995) Blood dyscrasias with carbamazepine and valproate: a pharmacoepidemiological study of 2,228 patients at risk. Am J Psychiatry 152:413\u2013418","journal-title":"Am J Psychiatry"},{"key":"1701_CR36","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1345\/aph.17445","volume":"32","author":"M Cates","year":"1998","unstructured":"Cates M, Powers R (1998) Concomitant rash and blood dyscrasias in geriatric psychiatry patients treated with carbamazepine. Ann Pharmacother 32:884\u2013887","journal-title":"Ann Pharmacother"},{"key":"1701_CR37","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1080\/00325481.1990.11716370","volume":"88","author":"JG Bertolino","year":"1990","unstructured":"Bertolino JG (1990) Carbamazepine. What physicians should know about its hematologic effects. Postgrad Med 88:183\u2013186","journal-title":"Postgrad Med"},{"key":"1701_CR38","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1177\/106002809002401214","volume":"24","author":"JL Sobotka","year":"1990","unstructured":"Sobotka JL, Alexander B, Cook BL (1990) A review of carbamazepine\u2019s hematologic reactions and monitoring recommendations. DICP 24:1214\u20131219","journal-title":"DICP"},{"key":"1701_CR39","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.yebeh.2005.10.002","volume":"8","author":"AA Asadi-Pooya","year":"2006","unstructured":"Asadi-Pooya AA, Ghetmiri E (2006) Folic acid supplementation reduces the development of some blood cell abnormalities in children receiving carbamazepine. Epilepsy Behav 8:228\u2013231","journal-title":"Epilepsy Behav"},{"key":"1701_CR40","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/0887-8994(94)90093-0","volume":"11","author":"GV Massey","year":"1994","unstructured":"Massey GV, Dunn NL, Heckel JL et al (1994) Aplastic anemia following therapy for absence seizures with ethosuximide. Pediatr Neurol 11:59\u201361","journal-title":"Pediatr Neurol"},{"key":"1701_CR41","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1111\/j.1651-2227.1983.tb09845.x","volume":"72","author":"M Seip","year":"1983","unstructured":"Seip M (1983) Aplastic anemia during ethosuximide medication. Treatment with bolus-methylprednisolone. Acta Paediatr Scand 72:927\u2013929","journal-title":"Acta Paediatr Scand"},{"key":"1701_CR42","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/S0387-7604(03)00060-3","volume":"27","author":"T Imai","year":"2003","unstructured":"Imai T, Okada H, Nanba M et al (2003) Ethosuximide induced agranulocytosis. Brain Dev 27:522\u2013524","journal-title":"Brain Dev"},{"key":"1701_CR43","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1212\/01.WNL.0000163997.67472.C5","volume":"64","author":"DL Steinweg","year":"2005","unstructured":"Steinweg DL, Bentley ML (2005) Seizures following reduction in phenytoin level after orally administered folic acid. Neurology 64:1982","journal-title":"Neurology"},{"key":"1701_CR44","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1177\/088307389901400212","volume":"14","author":"FK Alehan","year":"1999","unstructured":"Alehan FK, Russell EC, Pellock JM (1999) Phenytoin-associated thrombocytopenia in a toddler. J Child Neurol 14:130\u2013131","journal-title":"J Child Neurol"},{"key":"1701_CR45","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1177\/0897190009341308","volume":"23","author":"AM Ranzino","year":"2010","unstructured":"Ranzino AM, Sorrells KR, Manor SM (2010) Possible acute thrombocytopenia post esomeprazole and hydantoin coadministration. J Pharm Pract 23:140\u2013143","journal-title":"J Pharm Pract"},{"key":"1701_CR46","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1159\/000204838","volume":"86","author":"MJ Sharafuddin","year":"1991","unstructured":"Sharafuddin MJ, Spanheimer RG, McClune GL (1991) Phenytoin-induced agranulocytosis: a nonimmunologic idiosyncratic reaction? Acta Haematol 86:212\u2013213","journal-title":"Acta Haematol"},{"key":"1701_CR47","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1182\/blood.V54.2.501.501","volume":"54","author":"R Taetle","year":"1979","unstructured":"Taetle R, Lane TA, Mendelsohn J (1979) Drug-induced agranulocytosis: in vitro evidence for immune suppression of granulopoiesis and a cross-reacting lymphocyte antibody. Blood 54:501\u2013512","journal-title":"Blood"},{"key":"1701_CR48","first-page":"713","volume":"28","author":"S Tanaka","year":"2000","unstructured":"Tanaka S, Toujou H, Tara M, Uetsuhara K (2000) Diphenylhydantoin-induced pure red cell aplasia after neurological surgery: report of two cases. No Shinkei Geka 28:713\u2013717","journal-title":"No Shinkei Geka"},{"key":"1701_CR49","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1182\/blood.V30.5.587.587","volume":"30","author":"AA Yunis","year":"1967","unstructured":"Yunis AA, Arimura GK, Lutcher CL et al (1967) Biochemical lesion in dilantin-induced erythroid aplasia. Blood 30:587\u2013600","journal-title":"Blood"},{"key":"1701_CR50","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1182\/blood.V65.4.789.789","volume":"65","author":"EN Dessypris","year":"1985","unstructured":"Dessypris EN, Redline S, Harris JW, Krantz SB (1985) Diphenylhydantoin-induced pure red cell aplasia. Blood 65:789\u2013794","journal-title":"Blood"},{"key":"1701_CR51","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.2169\/internalmedicine.49.4026","volume":"49","author":"A Sugaya","year":"2010","unstructured":"Sugaya A, Nakamagoe K, Okoshi Y et al (2010) Diphenylhydantoin-induced severe yet reversible anemia during pregnancy. Intern Med 49:2515\u20132518","journal-title":"Intern Med"},{"key":"1701_CR52","doi-asserted-by":"crossref","first-page":"69","DOI":"10.4103\/0028-3886.76866","volume":"59","author":"G Paul","year":"2011","unstructured":"Paul G, Sood P, Berry A, Paul BS (2011) Pure red cell aplasia with phenytoin following traumatic brain injury. Neurol India 59:69\u201370","journal-title":"Neurol India"},{"key":"1701_CR53","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1182\/blood.V61.5.889.889","volume":"61","author":"WT Gerson","year":"1983","unstructured":"Gerson WT, Fine DG, Spielberg SP, Sensenbrenner LL (1983) Anticonvulsant-induced aplastic anemia: increased susceptibility to toxic drug metabolites in vitro. Blood 61:889\u2013893","journal-title":"Blood"},{"key":"1701_CR54","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1046\/j.1532-5415.2002.50083.x","volume":"50","author":"H Blain","year":"2002","unstructured":"Blain H, Hamdan KA, Blain A, Jeandel C (2002) Aplastic anemia induced by phenytoin: a geriatric case with severe folic acid deficiency. JAGS 50:396\u2013401","journal-title":"JAGS"},{"key":"1701_CR55","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1159\/000205989","volume":"77","author":"O Shalev","year":"1987","unstructured":"Shalev O, Gilon D, Nubani NH (1987) Masked phenytoin-induced megaloblastic anemia in beta-thalassemia minor. Acta Haematol 77:186\u2013187","journal-title":"Acta Haematol"},{"key":"1701_CR56","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/ajh.2830100307","volume":"10","author":"JE Menitove","year":"1981","unstructured":"Menitove JE, Rassiga AL, McLaren GD et al (1981) Antigranulocyte antibodies and deranged immune function associated with phenytoin-induced serum sickness. Am J Hematol 10:277\u2013284","journal-title":"Am J Hematol"},{"key":"1701_CR57","doi-asserted-by":"crossref","first-page":"121","DOI":"10.3171\/jns.1993.79.1.0121","volume":"79","author":"A Rawanduzy","year":"1993","unstructured":"Rawanduzy A, Sarkis A, Rovit RL (1993) Severe phenytoin-induced bone marrow depression and agranulocytosis treated with human recombinant granulocyte-macrophage colony-stimulating factor. J Neurosurg 79:121\u2013124","journal-title":"J Neurosurg"},{"key":"1701_CR58","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1182\/blood.V30.3.341.341","volume":"30","author":"MB Dahlke","year":"1967","unstructured":"Dahlke MB, Mertens-Roesler E (1967) Malabsorption of folic acid due to diphenylhydantoin. Blood 30:341\u2013351","journal-title":"Blood"},{"key":"1701_CR59","first-page":"45","volume":"27","author":"CF Hawkins","year":"1958","unstructured":"Hawkins CF, Meynell MJ (1958) Macrocytosis and macrocytic anaemia caused by anticonvulsant drugs. Q Med J 27:45","journal-title":"Q Med J"},{"key":"1701_CR60","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1542\/peds.32.3.376","volume":"32","author":"SB Kahn","year":"1963","unstructured":"Kahn SB, Lischner H, Baker L, Williams WJ (1963) Megaloblastic anemia associated with the ingestion of phenobarbital and primidone. Report of a case in a six-year-old child. Pediatrics 32:376\u2013383","journal-title":"Pediatrics"},{"key":"1701_CR61","first-page":"368","volume":"82","author":"AL Sherwin","year":"1960","unstructured":"Sherwin AL, Wait RH, Cooper BA (1960) Megloblastic anaemia associated with phenobarbital therapy. Can Med Assoc J 82:368","journal-title":"Can Med Assoc J"},{"key":"1701_CR62","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1159\/000114096","volume":"119","author":"D Focosi","year":"2008","unstructured":"Focosi D, Kast RE, Benedetti E et al (2008) Phenobarbital-associated bone marrow aplasia: a case report and review of the literature. Acta Haematol 119:18\u201321","journal-title":"Acta Haematol"},{"key":"1701_CR63","first-page":"304","volume":"48","author":"K John","year":"1980","unstructured":"John K, Hermann J, H\u00e4ssler A, John R (1980) Panmyelopathy in combined epilepsy therapy using ethosuccimide, diphenylhydantoin, and phenobarbital in childhood. Kinderarztl Prax 48:304\u2013310","journal-title":"Kinderarztl Prax"},{"key":"1701_CR64","doi-asserted-by":"crossref","first-page":"527","DOI":"10.2131\/jts.34.527","volume":"34","author":"S Kojima","year":"2009","unstructured":"Kojima S, Sasaki J, Tomita M et al (2009) Multiple organ toxicity, including hypochromic anemia, following repeated administration of PB in rats. J Toxicol Sci 34:527\u2013539","journal-title":"J Toxicol Sci"},{"key":"1701_CR65","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1111\/j.1748-5827.2008.00564.x","volume":"49","author":"A Khoutorsky","year":"2008","unstructured":"Khoutorsky A, Bruchim Y (2008) Transient leucopenia, thrombocytopenia and anaemia associated with severe acute phenobarbital intoxication in a dog. J Small Anim Pract 49:367\u2013369","journal-title":"J Small Anim Pract"},{"key":"1701_CR66","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1212\/WNL.24.10.920","volume":"24","author":"GE Solomon","year":"1974","unstructured":"Solomon GE, Hilgartner MW, Kutt H (1974) Phenobarbital-induced coagulation defects in cats. Neurology 24:920\u2013924","journal-title":"Neurology"},{"key":"1701_CR67","first-page":"94","volume":"29","author":"PW Ferguson","year":"1979","unstructured":"Ferguson PW, Anderson JH, Krieger RI (1979) Secondary thrombocytopenia following phenobarbital treatments in a rhesus monkey (Macaca mulatta). Lab Anim Sci 29:94\u201396","journal-title":"Lab Anim Sci"},{"key":"1701_CR68","first-page":"245","volume":"60","author":"U Taliani","year":"1989","unstructured":"Taliani U, Camellini A, Bernardi P et al (1989) A clinical case of severe megaloblastic anemia during treatment with primidone. Acta Biomed Ateneo Parmense 60:245\u2013248","journal-title":"Acta Biomed Ateneo Parmense"},{"key":"1701_CR69","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1136\/bmj.2.5088.80","volume":"2","author":"I Chanarin","year":"1958","unstructured":"Chanarin I, Elmes PC, Mollin DL (1958) Folic acid studies in megaloblastic anaemia due to primidone. Br Med J 2:80\u201382","journal-title":"Br Med J"},{"key":"1701_CR70","doi-asserted-by":"crossref","first-page":"559","DOI":"10.7326\/0003-4819-81-4-559","volume":"81","author":"WA Parker","year":"1974","unstructured":"Parker WA (1974) Primidone thrombocytopenia. Ann Intern Med 81:559\u2013560","journal-title":"Ann Intern Med"},{"key":"1701_CR71","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1111\/j.1528-1167.2006.00587.x","volume":"47","author":"T Gerstner","year":"2006","unstructured":"Gerstner T, Teich M, Bell N et al (2006) Valproate-associated coagulopathies are frequent and variable in children. Epilepsia 47:1136\u20131143","journal-title":"Epilepsia"},{"key":"1701_CR72","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1111\/j.1528-1167.2007.01429.x","volume":"49","author":"W Nasreddine","year":"2008","unstructured":"Nasreddine W, Beydoun A (2008) Valproate-induced thrombocytopenia: a prospective monotherapy study. Epilepsia 49:438\u2013445","journal-title":"Epilepsia"},{"key":"1701_CR73","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1034\/j.1600-0404.2003.00149.x","volume":"108","author":"B Pohlmann-Eden","year":"2003","unstructured":"Pohlmann-Eden B, Peters CNA, Wennberg R, Dempfle CE (2003) Valproate induces reversible factor XIII deficiency with risk of perioperative bleeding. Acta Neurol Scand 108:142\u2013145","journal-title":"Acta Neurol Scand"},{"key":"1701_CR74","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.0013-9580.2004.28302.x","volume":"45","author":"M Teich","year":"2004","unstructured":"Teich M, Longin E, Dempfle CE, K\u00f6nig S (2004) Factor XIII deficiency associated with valproate treatment. Epilepsia 45:187\u2013189","journal-title":"Epilepsia"},{"key":"1701_CR75","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1111\/j.1528-1157.1992.tb02303.x","volume":"33","author":"W Kreuz","year":"1992","unstructured":"Kreuz W, Linde R, Funk M et al (1992) Valproate therapy induces von Willebrand disease type I. Epilepsia 33:178\u2013184","journal-title":"Epilepsia"},{"key":"1701_CR76","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1212\/WNL.44.8.1418","volume":"44","author":"B Gidal","year":"1994","unstructured":"Gidal B, Spencer N, Maly M et al (1994) Valproate-mediated disturbances of hemostasis: relationship to dose and plasma concentration. Neurology 44:1418\u20131422","journal-title":"Neurology"},{"key":"1701_CR77","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1182\/blood.V69.6.1691.1691","volume":"69","author":"JC Gill","year":"1987","unstructured":"Gill JC, Endres-Brooks J, Bauer PJ et al (1987) The effect of ABO blood group on the diagnosis of von Willebrand disease. Blood 69:1691\u20131695","journal-title":"Blood"},{"key":"1701_CR78","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1007\/s001120050487","volume":"147","author":"SA K\u00f6nig","year":"1999","unstructured":"K\u00f6nig SA, Eiger CE, Vasella F (1999) Empfehlungen zur Blutuntersuchung und der klinischen \u00dcberwachung zur Fr\u00fcherkennung des Valproat-assoziierten Leberversagens. Mschr Kinderheilk 147:718\u2013723","journal-title":"Mschr Kinderheilk"},{"key":"1701_CR79","first-page":"304","volume":"24","author":"W Kreuz","year":"1994","unstructured":"Kreuz W, Mentzer D, Becker S et al (1994) Haemate P in children with von Willebrand\u2019s disease. Haemostasis 24:304\u2013310","journal-title":"Haemostasis"},{"key":"1701_CR80","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1055\/s-0037-1616942","volume":"29","author":"W Eberl","year":"2009","unstructured":"Eberl W, Budde U, Bentele K et al (2009) Acquired von Willebrand syndrome as side effect of valproic acid therapy in children is rare. H\u00e4mostaseologie 29:137\u2013142","journal-title":"H\u00e4mostaseologie"},{"key":"1701_CR81","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.pediatrneurol.2008.10.005","volume":"40","author":"\u00d6 \u00dcnal","year":"2009","unstructured":"\u00dcnal \u00d6, Deda G, Teber S et al (2009) Thrombophilic risk factors in epileptic children treated with valproic acid. Pediatr Neurol 40:102\u2013106","journal-title":"Pediatr Neurol"},{"key":"1701_CR82","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.braindev.2006.03.009","volume":"28","author":"M Ugras","year":"2006","unstructured":"Ugras M, Yakinci C (2006) Protein C, protein S and other pro- and anticoagulant activities among epileptic children using sodium valproate. Brain Dev 28:549\u2013553","journal-title":"Brain Dev"},{"key":"1701_CR83","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/S0022-3476(05)81105-9","volume":"117","author":"RG Watts","year":"1990","unstructured":"Watts RG, Emanuel PD, Zuckerman KS, Howard TH (1990) Valproic acid-induced cytopenias: evidence for a dose-related suppression of hematopoiesis. J Pediatr 117:495\u2013499","journal-title":"J Pediatr"},{"key":"1701_CR84","first-page":"743","volume-title":"Hematology: basic principles and practice","author":"JT Curnutte","year":"2000","unstructured":"Curnutte JT, Coates TD (2000) Disorders of phagocyte function and number. In: Hoffman R, Benz EJ Jr, Shattil SJ et al (eds) Hematology: basic principles and practice, 3rd edn. Churchill Livingstone, New York, pp 743\u2013745","edition":"3"},{"key":"1701_CR85","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1345\/aph.1C381","volume":"37","author":"KS Vesta","year":"2003","unstructured":"Vesta KS, Medina PJ (2003) Valproic acid-induced neutropenia. Ann Pharmacother 37:819\u2013821","journal-title":"Ann Pharmacother"},{"key":"1701_CR86","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1097\/00043426-200001000-00012","volume":"22","author":"A Suchitra","year":"2000","unstructured":"Suchitra A, James B (2000) Hematologic toxicity of sodium valproate. J Pediatr Hematol 22:62\u201365","journal-title":"J Pediatr Hematol"},{"key":"1701_CR87","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1111\/j.1528-1157.1997.tb00062.x","volume":"38","author":"DW Kaufman","year":"1997","unstructured":"Kaufman DW, Kelly JP, Anderson T et al (1997) Evaluation of case reports of aplastic anemia among patients treated with felbamate. Epilepsia 38:1265\u20131269","journal-title":"Epilepsia"},{"key":"1701_CR88","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1212\/WNL.44.5.980","volume":"44","author":"GC Ney","year":"1994","unstructured":"Ney GC, Schaul N, Loughlin J et al (1994) Thrombocytopenia in association with adjunctive felbamate use. Neurology 44:980\u2013981","journal-title":"Neurology"},{"key":"1701_CR89","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.clon.2004.06.015","volume":"16","author":"E Derbyshire","year":"2004","unstructured":"Derbyshire E, Martin D (2004) Neutropenia occurring after starting gabapentin for neuropathic pain. Clin Oncol (R Coll Radiol) 16:575\u2013576","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"1701_CR90","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1684\/j.1950-6945.2006.tb00285.x","volume":"8","author":"S Kilbas","year":"2006","unstructured":"Kilbas S (2006) Lamotrigine-induced leucopenia. Epileptic Disord 8:317","journal-title":"Epileptic Disord"},{"key":"1701_CR91","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.jemermed.2010.05.060","volume":"42","author":"M Okur","year":"2012","unstructured":"Okur M (2012) Lamotrigine-associated thrombocytopenia and leukopenia. J Emerg Med 42:584\u2013587","journal-title":"J Emerg Med"},{"key":"1701_CR92","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1111\/j.1528-1167.2010.02788.x","volume":"51","author":"K Sahaya","year":"2010","unstructured":"Sahaya K, Goyal MK, Sarwal A, Singh NN (2010) Levetiracetam-induced thrombocytopenia among inpatients: a retrospective study. Epilepsia 51:2492\u20132495","journal-title":"Epilepsia"},{"key":"1701_CR93","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/j.1600-0404.2006.00657.x","volume":"114","author":"J Bauer","year":"2006","unstructured":"Bauer J, Ben-Menachem E, Kramer G et al (2006) Levetiracetam: a long-term follow-up study of efficacy and safety. Acta Neurol Scand 114:169\u2013176","journal-title":"Acta Neurol Scand"},{"key":"1701_CR94","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/j.1527-3458.2007.00005.x","volume":"13","author":"T Smedt De","year":"2007","unstructured":"De Smedt T, Raedt R, Vonck K et al (2007) Levetiracetam: part II, the clinical profile of a novel anticonvulsant drug. CNS Drug Rev 13:57\u201378","journal-title":"CNS Drug Rev"},{"key":"1701_CR95","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1046\/j.1528-1157.2002.13101.x","volume":"43","author":"TA Glauser","year":"2002","unstructured":"Glauser TA, Pellock JM, Bebm EM et al (2002) Efficacy and safety of levetiracetam in children with partial seizures: an open-label trial. Epilepsia 43:518\u2013524","journal-title":"Epilepsia"},{"key":"1701_CR96","doi-asserted-by":"crossref","first-page":"747","DOI":"10.2165\/11319450-000000000-00000","volume":"29","author":"M Gallerani","year":"2009","unstructured":"Gallerani M, Mari E, Boari B et al (2009) Pancytopenia associated with levetiracetam treatment. Clin Drug Investig 29:747\u2013751","journal-title":"Clin Drug Investig"},{"key":"1701_CR97","first-page":"97","volume":"107","author":"P Boon","year":"2007","unstructured":"Boon P, Hulhoven R, Offner F (2007) Levetiracetam and bleeding disorders. Acta Neurol Belg 107:97\u2013102","journal-title":"Acta Neurol Belg"},{"key":"1701_CR98","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1345\/aph.1L727","volume":"43","author":"B Elouni","year":"2009","unstructured":"Elouni B, Ben Salem C, Biour M (2009) Levetiracetam-induced pancytopenia. Ann Pharmacother 43:985","journal-title":"Ann Pharmacother"},{"key":"1701_CR99","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.eplepsyres.2009.04.003","volume":"86","author":"M Hacquard","year":"2009","unstructured":"Hacquard M, Richard S, Lacour JC et al (2009) Levetiracetam-induced platelet dysfunction. Epilepsy Res 86:94\u201396","journal-title":"Epilepsy Res"},{"key":"1701_CR100","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1176\/appi.neuropsych.20.4.502","volume":"20","author":"A Milia","year":"2008","unstructured":"Milia A, Pilia G, Mascia MG et al (2008) Oxcarbazepine-induced leukopenia. J Neuropsychiatry Clin Neurosci 20:502\u2013503","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"1701_CR101","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1176\/appi.psy.47.1.73","volume":"47","author":"J Mahmud","year":"2006","unstructured":"Mahmud J, Mathews M, Verma S, Basil B (2006) Oxcarbazepine-induced thrombocytopenia. Psychosomatics 47:73\u201374","journal-title":"Psychosomatics"},{"key":"1701_CR102","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1097\/JCP.0b013e3181c97c29","volume":"30","author":"YT Hsiao","year":"2010","unstructured":"Hsiao YT, Wei IH, Huang CC (2010) Oxcarbazepine-related neutropenia: a case report. J Clin Psychopharmacol 30:94\u201395","journal-title":"J Clin Psychopharmacol"},{"key":"1701_CR103","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/01.jcp.0000264971.92828.b2","volume":"27","author":"MR Calamaras","year":"2007","unstructured":"Calamaras MR, Stowe ZN, Newport DJ (2007) Pancytopenia associated with the introduction of oxcarbazepine. J Clin Psychopharmacol 27:217\u2013218","journal-title":"J Clin Psychopharmacol"},{"key":"1701_CR104","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/MJT.0b013e31815afb6f","volume":"15","author":"MM Chaudhry","year":"2008","unstructured":"Chaudhry MM, Abrar M, Mutahir K, Mendoza C (2008) Oxcarbazepine-induced hemolytic anemia in a geriatric patient. Am J Ther 15:187\u2013189","journal-title":"Am J Ther"},{"key":"1701_CR105","unstructured":"Physician Desk Reference (2000) p. 2214, p. 2394"},{"key":"1701_CR106","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/0140-6736(91)90410-Q","volume":"338","author":"SL Gerson","year":"1991","unstructured":"Gerson SL, Lieberman JA, Friedenberg WR et al (1991) Polypharmacy in fatal clozapine-associated agranulocytosis. Lancet 338:262","journal-title":"Lancet"},{"key":"1701_CR107","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s00787-004-0323-0","volume":"13","author":"D Behar","year":"2004","unstructured":"Behar D, Schaller JL (2004) Topiramate leukopenia on clozapine. Eur Child Adolesc Psychiatry 13:51\u201352","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"1701_CR108","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1046\/j.1528-1157.2002.42401.x","volume":"43","author":"E Longin","year":"2002","unstructured":"Longin E, Teich M, Koelfen W, K\u00f6nig S (2002) Topiramate enhances the risk of valproate-associated side effects in three children. Epilepsia 43:451\u2013454","journal-title":"Epilepsia"},{"key":"1701_CR109","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/j.1365-2141.1988.tb02382.x","volume":"69","author":"A Tichelli","year":"1988","unstructured":"Tichelli A, Gratwohl A, Wursch A et al (1988) Late haematological complications in severe aplastic anaemia. Br J Haematol 69:413\u2013418","journal-title":"Br J Haematol"},{"key":"1701_CR110","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1136\/jnnp.69.6.711","volume":"69","author":"J Palace","year":"2000","unstructured":"Palace J, Lang B (2000) Epilepsy: an autoimmune disease? J Neurol Neurosurg Psychiatry 69:711\u2013714","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1701_CR111","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1345\/aph.1P335","volume":"44","author":"A Siniscalchi","year":"2010","unstructured":"Siniscalchi A, Gallelli L, Calabr\u00f2 G et al (2010) Phenobarbital\/lamotrigine coadministration-induced blood dyscrasia in a patient with epilepsy. Ann Pharmacother 44:2031\u20132034","journal-title":"Ann Pharmacother"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-014-1701-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10072-014-1701-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-014-1701-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T23:04:04Z","timestamp":1716591844000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10072-014-1701-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3,12]]},"references-count":111,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2014,7]]}},"alternative-id":["1701"],"URL":"https:\/\/doi.org\/10.1007\/s10072-014-1701-0","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,3,12]]}}}